Bring neurology discoveries to light with the SomaScan® Assay
Detect low-abundance proteins in complex sample types, including cerebrospinal fluid and blood.
Navigate the complex neurology landscape
Nearly 100 million people in the United States alone suffer from 1 of more than 1,000 different neurologic diseases.1 These diseases can derive from various sources such as faulty genes, problems with development of the nervous system, degeneration of the nervous system, dysfunctional proteins, and signaling pathways.2-4
The SomaScan Platform is the proteomics solution for targeted research into the biology of specific neurologic diseases. By utilizing high-content profiling for discovery of potential biomarkers, the platform can be used to further the study of a range of neurologic diseases including Alzheimer’s disease and Parkinson’s disease, spinal cord disorders, as well as cancer.5-9 In addition, our proteomics approach can be used to identify and track blood- and cerebrospinal fluid–based biomarkers as predictors of disease and indicators of disease progression.5,10
Look deeper with the SomaScan Platform
Multiplex, high-throughput proteomics
Screen up to 7,000 proteins per sample and conduct high-throughput analysis of >1,000 samples simultaneously.5
Detect and quantify a wide dynamic range of proteins (from fmol – µmol) in complex sample types including cerebrospinal fluid and blood.5,10
Obtain consistent and reproducible inter- and intra-assay results for data analysis and comparison.5
Harnessing AI and proteomics for glioblastoma
Andra Krauze, MD, Physician Early Investigator and radiation oncologist at NCI NIH, presents data on balancing genomics, transcriptomics, metabolomics, and proteomics — including approaches on how to connect proteomic data to the clinic.
Read more published research from Dr. Krauze on using the SomaScan® Assay for noninvasive glioblastoma classification and treatment response insights in
Frontiers in Oncology here.
Proteomics of neuro and aging
Learn how 5 experts use high-plex protein profiling in their research on aging, neurology, Alzheimer’s disease, sleep research, and pain therapeutics.
Tony Wyss-Coray, PhD, Stanford University
Naisha Shah, PhD, BioAge Labs
Sara Ahadi, PhD, Alkahest
Emmanuel Mignot, MD, PhD, Stanford University
Juliet Mwirigi, PhD candidate, UT Dallas
Genomic atlas of the proteome from brain, CSF and plasma identifies causal and druggable proteins implicated for neurological disorders
Carlos Cruchaga, PhD, Washington University in St. Louis, presents results from the first multi-tissue study yielding hundreds of novel pQTLs. The team identified 15 existing drugs approved for Alzheimer’s disease and another 14 for Parkinson’s disease.
Using plasma proteomics to understand diseases of the brain: Alzheimer’s and cerebral small vessel disease
Keenan Walker, PhD, Tenure-Track Investigator at NIA NIH, explains how proteins measured in blood decades before dementia onset can be combined with genetic data to identify early biomarkers and better understand the molecular pathways altered in the preclinical and prodromal phase of neurodegenerative disease.
Advanced proteomics offerings in neurology
The SomaScan Platform is available in multiple formats, each providing unique data outputs to fast-track your neurology research.
With the ability to profile 7,000 proteins simultaneously, the SomaScan Assay is well-suited to measuring low and highly abundant proteins in a small amount of blood or cerebrospinal fluid.5,10
These custom panels can be individualized from our menu of 7,000 protein analytes. The assay is also offered as a neuroscience panel containing 1,316 preset analytes most relevant to neurology-focused proteomics. This panel focuses on significant neurologic disease associations including Alzheimer’s disease, Parkinson’s disease, spinal cord disorders, cancer, ischemia, seizures, addiction, pain, and others.5
Monitor clinical metrics, including those associated with dementia and other critical parameters such as cardiovascular fitness and glucose tolerance.5,11
BLOGProteomic profiling in cerebrospinal fluid: advancing biomarker discovery in neurologyWith nearly 100 million people in the United States alone suffering from a neurologic disease, there is an urgent need for reliable biomarkers to aid in diagnosis, monitoring, and development of new treatments.1,2
White paperThe SomaScan® Assay enables discovery of blood-based biomarkers in neurodegenerative diseasesBlood-based biomarkers show promise as a minimally invasive, cost-effective option for the detection, classification, and monitoring of neurologic diseases.1-3
WebinarUsing non-hypothesized based approaches for biomarker developmentCurrent biomarkers are only moderately predictive in identifying individuals with mild traumatic brain injury or concussion. Therefore, more accurate diagnostic markers are needed for sport-related concussion (SRC).
References: 1. Gooch CL, Pracht E, Borenstein AR. The burden of neurological disease in the United States: a summary report and call to action. Ann Neurol. 2017;81(4):479-484. doi:10.1002/ana.24897. 2. Moujalled D, Strasser A, Liddell JR. Molecular mechanisms of cell death in neurological diseases. Cell Death Differ. 2021;28(7):2029-2044. doi:10.1038/s41418-021-00814-y. 3. McKinnon PJ. DNA repair deficiency and neurological disease. Nat Rev Neurosci. 2009;10(2):100-112. doi:10.1038/nrn2559. 4. Sweeney P, Park H, Baumann M, et al. Protein misfolding in neurodegenerative diseases: implications and strategies. Transl Neurodegener. 2017;6:6. doi:10.1186/s40035-017-0077-5. 5. Data on file. SomaLogic Operating Co., Inc. 6. Ward M, Schofield EL. Biomarkers for brain disorders. Therapy. 2010;7(4):321-336. 7. Shi L, Winchester LM, Westwood S, et al. Replication study of plasma proteins relating to Alzheimer’s pathology. Alzheimers Dement. 2021;17(9):1452-1464. doi:10.1002/alz.12322. 8. Yang C, Farias FHG, Ibanez L, et al. Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. Nat Neurosci. 2021;24(9):1302-1312. doi:10.1038/s41593-021-00886-6. 9. Candia J, Cheung F, Kotliarov Y, et al. Assessment of variability in the SOMAscan Assay. Sci Rep. 2017;7(1):14248. doi:10.1038/s41598-017-14755-5. 10. Masvekar R, Wu T, Kosa P, Barbour C, Fossati V, Bielekova B. Cerebrospinal fluid biomarkers link toxic astrogliosis and microglial activation to multiple sclerosis severity. Mult Scler Relat Disord. 2019;28:34-43. doi:10.1016/j.msard.2018.11.032. 11. Walker KA, Chen J, Zhang J, et al. Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk. Nat Aging. 2021;1:473-489. doi:10.1038/s43587-021-00064-0.